Placebo for BHV-7000
Sponsors
Biohaven Therapeutics Ltd.
Conditions
Idiopathic Generalized Epilepsy with Generalized Tonic-clonic SeizuresRefractory Focal Onset Epilepsy
Phase 2
A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy
RecruitingCTIS2023-508539-30-00
Start: 2024-10-10Target: 219Updated: 2025-03-21
A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy
RecruitingCTIS2023-508811-21-00
Start: 2024-09-25Target: 221Updated: 2026-01-19
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BHV-7000 as Adjunctive Therapy in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures, with Open-label Extension
RecruitingCTIS2023-508812-45-00
Start: 2024-11-11Target: 122Updated: 2025-09-12